XML 49 R32.htm IDEA: XBRL DOCUMENT v3.24.0.1
OPERATING BUSINESS SEGMENT AND INTERNATIONAL OPERATION INFORMATION (Tables)
 12 Months Ended
Dec. 31, 2023
Segment Reporting [Abstract]  
Schedule of reportable business segment information
Reportable business segment information for the years ended December 31, 2023 and 2022 is as follows (dollar amounts in thousands):
Year Ended December 31,20232022
Net sales:  
Asia$201,251 $186,292 
Europe81,101 78,991 
North America139,804 133,214 
Latin America and Other23,164 23,413 
Total net sales445,320 421,910 
Contribution margin (1):  
Asia96,365 85,876 
Europe25,456 25,911 
North America54,877 47,615 
Latin America and Other9,109 9,981 
Total contribution margin185,807 169,383 
Selling, general and administrative (2)167,058 153,125 
Operating income18,749 16,258 
Other income (loss), net1,453 (1,043)
Income before provision for income taxes$20,202 $15,215 
___________________________
(1) Contribution margin consists of net sales less cost of sales and volume incentives expense.

(2) Service fees in China totaled $16.6 million and $14.9 million for the years ended December 31, 2023 and 2022, respectively. These service fees are included in our selling, general and administrative expenses.

Year Ended December 31,20232022
Capital expenditures:  
Asia$1,882 $1,830 
Europe138 57 
North America8,431 5,573 
Latin America and Other27 168 
Total capital expenditures$10,478 $7,628 
Depreciation and amortization:  
Asia$1,812 $1,856 
Europe54 123 
North America9,890 8,863 
Latin America and Other60 183 
Total depreciation and amortization$11,816 $11,025 
As of December 31,20232022
Assets:  
Asia$105,636 $95,362 
Europe20,920 15,773 
North America116,052 112,319 
Latin America and Other7,165 6,324 
Total assets$249,773 $229,778 
Schedule of consolidated net sales revenue by geographical locations
From an individual country/region perspective, only the United States, South Korea and Taiwan comprise 10 percent or more of consolidated net sales for the years ended December 31, 2023 and 2022 as follows (dollar amounts in thousands):
Year Ended December 31,20232022
Net sales:  
United States$129,305 $122,863 
Taiwan61,691 48,474 
South Korea49,845 54,935 
Other204,479 195,638 
Total net sales$445,320 $421,910 
Schedule of revenue generated by each of the Company's product lines
Revenue generated by each of our product lines is set forth below (dollars in thousands):
Year Ended December 31,20232022
Asia:  
General health$69,037 $53,603 
Immunity5,420 3,283 
Cardiovascular57,771 55,312 
Digestive36,434 37,457 
Personal care5,586 9,205 
Weight management27,003 27,432 
 201,251 186,292 
Europe:  
General health$34,709 $34,438 
Immunity8,222 8,489 
Cardiovascular9,143 9,380 
Digestive22,111 20,024 
Personal care4,977 4,854 
Weight management1,939 1,806 
 81,101 78,991 
North America:  
General health$63,742 $64,488 
Immunity16,124 14,966 
Cardiovascular14,959 14,383 
Digestive34,628 28,490 
Personal care6,476 6,212 
Weight management3,875 4,675 
 139,804 133,214 
Latin America and Other:  
General health$6,286 $6,728 
Immunity2,703 2,901 
Cardiovascular1,718 1,662 
Digestive10,693 10,040 
Personal care1,262 1,399 
Weight management502 683 
 23,164 23,413 
Total net sales$445,320 $421,910 
Schedule of consolidated property, plant and equipment by geographical locations
From an individual country perspective, only the United States comprise 10 percent or more of consolidated property, plant and equipment as follows (dollar amounts in thousands):
As of December 31 20232022
Property, plant and equipment, net  
United States$41,239 $42,389 
Other3,761 3,773 
Total property, plant and equipment$45,000 $46,162